Incorporating multiple antigens addresses the heterogeneity of TNBC and mitigates the risk of antigen-negative variant escape—a limitation observed in single-antigen vaccines such as HER2-targeted approaches in DCIS (10). This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.